Type I Gaucher Disease Following Chemotherapy for Light Chain Multiple Myeloma

DOI Web Site 参考文献18件
  • Cheung Winson Y.
    Department of Internal Medicine, University of Manitoba, Winnipeg
  • Greenberg Cheryl R.
    Department of Pediatrics and Child Health, University of Manitoba, Winnipeg
  • Bernstein Keevin
    Department of Internal Medicine, University of Manitoba, Winnipeg Section of Nephrology, University of Manitoba, Winnipeg
  • Schacter Brent
    Cancer Care Manitoba, University of Manitoba, Winnipeg
  • Fourie Thomas
    Pathology, University of Manitoba, Winnipeg
  • Seftel Matthew D.
    Department of Internal Medicine, University of Manitoba, Winnipeg Cancer Care Manitoba, University of Manitoba, Winnipeg Section of Hematology and Medical Oncology, University of Manitoba, Winnipeg

この論文をさがす

抄録

Although plasma cell disorders, such as hypergammaglobulinemia and monoclonal gammopathy of undetermined significance (MGUS), are reported to occur at higher incidences in patients with Type I Gaucher disease (GD) than in the normal population, pure light chain multiple myeloma (LCMM) has never been described in this context. Our case is the first to highlight a patient with LCMM who developed clinically apparent GD only following chemotherapy and hematopoietic stem cell transplantation. Renal complications are also exceedingly rare in GD, but nephrotic syndrome is one of the presenting features in this patient. The findings from this case will have important screening and diagnostic implications for both clinicians and patients.<br>

収録刊行物

  • Internal Medicine

    Internal Medicine 46 (15), 1255-1258, 2007

    一般社団法人 日本内科学会

参考文献 (18)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ